IPSC · Century Therapeutics, Inc.
$2.24
+0.05 (+2.28%)
At close · Jul 21
Market Cap
$403.99M
Shares
180.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.24
Open$2.23
Day$2.18–2.24
52W$0.44–3.04
Avg vol 30d1.7M
Short int23.5M · 13.0% float · 7.8d
Short vol57%
Last earningsMar 19, 2025
DataJun 2021–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
−1%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
69%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−15%
trailing
YTD return
+125%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
5 of 74 funds reported for Jun 30 · net +32.8K sh shares · +2 new
Insider flow
Distributing
Net -$11.7K over 90 days · 100% sells
Short interest
Rising
13.01% of float · ▲ +52.2% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
74 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+1557%
Y/Y
EPS growth
+91%
Y/Y
Free cash flow
$-104.7M
Balance sheet
$58.1M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
69%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
5 of 74 funds reported for Jun 30 · net +32.8K sh shares · +2 new
Insider flow
Distributing
Net -$11.7K over 90 days · 100% sells
Short interest
Rising
13.01% of float · ▲ +52.2% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
74 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $2 · 69%
52-wk high $3
vs 200-day avg +32%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IPSC
this stock
Century Therapeutics, Inc.
|
$403.99M | +125.1% | +1556.8% | — | 13.0% |
|
ONC
BeOne Medicines Ltd.
|
$460.58B | +4.9% | +22179.2% | 937.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.33B | +6.3% | +46.2% | 28.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.79B | -12.4% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$54.72B | +4.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IPSC | +5.2% | -2.6% | -15.5% | -8.6% | +125.1% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | +5.6% | -3.1% | -23.1% | -8.8% | +115.4% |